Cost-effectiveness of vitamin D and calcium supplementation in the treatment of elderly women and men with osteoporosis

European Journal of Public Health

Volumn 25, Issue 1, 2015, Pages 20-25

  Hiligsmann, Mickaël ^a   Sedrine, Wafa Ben ^b   Bruyère, Olivier ^b   Evers, Silvia M ^a   Rabenda, Véronique ^b   Reginster, Jean Yves ^b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; VITAMIN; VITAMIN D;

AGED; BONE DENSITY; COST BENEFIT ANALYSIS; DIET SUPPLEMENTATION; DRUG EFFECTS; ECONOMICS; FEMALE; GERIATRIC ASSESSMENT; HUMAN; MALE; MIDDLE AGED; OSTEOPOROSIS; PROCEDURES; QUALITY ADJUSTED LIFE YEAR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BONE DENSITY; CALCIUM; COST-BENEFIT ANALYSIS; DIETARY SUPPLEMENTS; FEMALE; GERIATRIC ASSESSMENT; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; QUALITY-ADJUSTED LIFE YEARS; VITAMIN D; VITAMINS;

EID: 84922477301     PISSN: 11011262     EISSN: 1464360X     Source Type: Journal    
DOI: 10.1093/eurpub/cku119     Document Type: Review

References (36)

1. Svedbom A, Hernlund E, Ivergard M, et al. Osteoporosis in the European Union: a compendium of country-specific reports. Arch Osteoporos 2013;8:137.
2. Boonen S, Lips P, Bouillon R, et al. Need for additional calcium to reduce the risk of hip fracture with vitamin d supplementation: evidence from a comparative metaanalysis of randomized controlled trials. J Clin Endocrinol Metab 2007;92: 1415-23.
3. Tang BM, Eslick GD, Nowson C, et al. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet 2007;370:657-66.
4. Kanis JA, McCloskey EV, Johansson H, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2013; 24:23-57.
5. Rizzoli R, Boonen S, Brandi ML, et al. The role of calcium and vitamin D in the management of osteoporosis. Bone 2008;42:246-9.
6. Si L, Winzenberg TM, Palmer AJ. A systematic review of models used in cost-effectiveness analyses of preventing osteoporotic fractures. Osteoporos Int 2014;25:51-60.
7. Hiligsmann M, Ethgen O, Bruyere O, et al. Development and validation of a Markov microsimulation model for the economic evaluation of treatments in osteoporosis. Value Health 2009;12:687-96.
8. Hiligsmann M, Ben Sedrine W, Bruyere O, Reginster JY. Cost-effectiveness of strontium ranelate in the treatment of male osteoporosis. Osteoporos Int 2013;24: 2291-300.
9. Hiligsmann M, Rabenda V, Gathon HJ, et al. Potential clinical and economic impact of nonadherence with osteoporosis medications. Calcif Tissue Int 2010;86:202-10.
10. Hiligsmann M, Reginster JY. Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in belgium. Pharmacoeconomics 2011;29:895-911.
11. Hiligsmann M, Ben Sedrine W, Reginster JY. Cost-effectiveness of bazedoxifene compared with raloxifene in the treatment of postmenopausal osteoporotic women. J Bone Miner Res 2013;28:807-15.
12. Hiligsmann M, Bruyere O, Roberfroid D, et al. Trends in hip fracture incidence and in the prescription of antiosteoporosis medications during the same time period in Belgium (2000-2007). Arthritis Care Res 2012;64:744-50.
13. Melton LJ III, Gabriel SE, Crowson CS, et al. Cost-equivalence of different osteo-porotic fractures. Osteoporos Int 2003;14:383-8.
14. Hiligsmann M, Ethgen O, Richy F, Reginster JY. Utility values associated with osteoporotic fracture: a systematic review of the literature. Calcif Tissue Int 2008;82: 288-92.
15. Silverman SL, Minshall ME, Shen W, et al. The relationship of health-related quality of life to prevalent and incident vertebral fractures in postmenopausal women with osteoporosis: results from the Multiple Outcomes of Raloxifene Evaluation Study. Arthritis Rheum 2001;44:2611-9.
16. Salaffi F, Cimmino MA, Malavolta N, et al. The burden of prevalent fractures on health-related quality of life in postmenopausal women with osteoporosis: the IMOF study. J Rheumatol 2007;34:1551-60.
17. Boonen S, Lips P, Bouillon R, et al. Need for additional calcium to reduce the risk of hip fracture with vitamin D supplementation: evidence from a comparative metaanalysis of randomized controlled trials. J Clin Endocrinol Metab 2007;92: 1415-23.
18. Kanis JA, Johnell O, Oden A, et al. Long-term risk of osteoporotic fracture in Malmo. Osteoporos Int 2000;11:669-74.
19. Johansson H, Kanis JA, McCloskey EV, et al. A FRAX(R) model for the assessment of fracture probability in Belgium. Osteoporos Int 2011;22:453-61.
20. Kanis JA, Oden A, Johnell O, et al. The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 2001;12:417-27.
21. Haentjens P, Magaziner J, Colon-Emeric CS, et al. Meta-analysis: excess mortality after hip fracture among older women and men. Ann Intern Med 2010;152:380-90.
22. Kanis JA, Oden A, Johnell O, et al. Excess mortality after hospitalisation for vertebral fracture. Osteoporos Int 2004;15:108-12.
23. Kanis JA, Oden A, Johnell O, et al. The components of excess mortality after hip fracture. Bone 2003;32:468-73.
24. Cleemput I, van Wilder P, Huybrechts M, Vrijens F. Belgian methodological guidelines for pharmacoeconomic evaluations: toward standardization of drug reimbursement requests. Value Health 2009;12:441-9.
25. Hiligsmann M, Gathon HJ, Bruyere O, et al. Hospitalisation costs of hip fractures in Belgium. Osteoporos Int 2011:Abstract. 11th ECCEO.
26. Autier P, Haentjens P, Bentin J, et al. Costs induced by hip fractures: a prospective controlled study in Belgium. Belgian Hip Fracture Study Group. Osteoporos Int 2000;11:373-80.
27. Reginster JY, Gillet P, Ben Sedrine W, et al. Direct costs of hip fractures in patients over 60 years of age in Belgium. Pharmacoeconomics 1999;15:507-14.
28. Bischoff-Ferrari HA, Willett WC, Wong JB, et al. Prevention of nonvertebral fractures with oral vitamin D and dose dependency: a meta-analysis of randomized controlled trials. Arch Intern Med 2009;169:551-61.
29. Zethraeus N, Borgstrom F, Strom O, et al. Cost-effectiveness of the treatment and prevention of osteoporosis-a review of the literature and a reference model. Osteoporos Int 2007;18:9-23.
30. Strom O, Borgstrom F, Sen SS, et al. Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries-an economic evaluation based on the fracture intervention trial. Osteoporos Int 2007;18: 1047-61.
31. Kanis JA, Oden A, McCloskey EV, et al. A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int 2012;23: 2239-56.
32. Rejnmark L, Avenell A, Masud T, et al. Vitamin D with calcium reduces mortality: patient level pooled analysis of 70, 528 patients from eight major vitamin D trials. J Clin Endocrinol Metab 2012;97:2670-81.
33. Lin J, Manson JE, Lee IM, et al. Intakes of calcium and vitamin D and breast cancer risk in women. Arch Intern Med 2007;167:1050-9.
34. Wang L, Manson JE, Song Y, Sesso HD. Systematic review: vitamin D and calcium supplementation in prevention of cardiovascular events. Ann Intern Med 2010;152: 315-23.
35. Moyer VA. Vitamin D and calcium supplementation to prevent fractures in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2013;158:691-6.
36. Bischoff-Ferrari HA, Willett WC, Orav EJ, et al. A pooled analysis of vitamin D dose requirements for fracture prevention. N Engl J Med 2012;367:40-9.